Top psych stories of September: Twice-yearly schizophrenia treatment, combating burnout

Healio Psychiatry has compiled a list of its five most-viewed stories in September.

The FDA’s approval of a twice-yearly schizophrenia treatment, a study on poor sleep increasing psychotic experiences among college students and a presentation on how to combat physician burnout and suicide top the list.

FDA approves twice-yearly schizophrenia treatment

The Janssen Pharmaceutical Companies of Johnson & Johnson announced FDA approval of Invega Hafyera, a twice-yearly injectable antipsychotic for adults with schizophrenia. Read more.

Poor sleep, social functioning increase psychotic experiences in college students

While poor sleep quality indicated better social functioning, poor sleep and social functioning were associated with increased psychotic-like experiences in college students, according to a study in Journal of Psychiatric Research. Read more.

Early intervention key to combating physician burnout, suicide

Ending physician suicide from burnout relies on early identification of and intervention for unwellness before it leads to impairment, according to a speaker at the Ending Physician Burnout Global Summit. Read more.

Eight online factors linked to suicidal behavior in youth

Cyberbullying, as well as content related to drugs, depression and violence, were major risk factors for subsequent youth suicide-related behavior, according to results of a matched case-control study published in JAMA Network Open. Read more.

Opioid overdose death rate increases 40% among Black individuals

Opioid overdose death rates increased among non-Hispanic Black individuals between 2018 and 2019, despite having leveled off overall, according to study results published in the American Journal of Public Health. Read more.